Trial Profile
A registration trial to investigate the effects of RP103 in patients with Huntington's disease
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 22 Dec 2016
Price :
$35
*
At a glance
- Drugs Mercaptamine bitartrate (Primary)
- Indications Huntington's disease
- Focus Registrational; Therapeutic Use
- 25 Oct 2016 This trial was planned by Raptor Pharmaceutical Corp. The company has now been acquired by Horizon Pharma plc, according to a Horizon Pharma plc media release.
- 14 Dec 2015 New trial record